Compare VLTO & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLTO | WAT |
|---|---|---|
| Founded | 2023 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7B | 29.3B |
| IPO Year | 2023 | 1996 |
| Metric | VLTO | WAT |
|---|---|---|
| Price | $87.08 | $303.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 17 |
| Target Price | $111.25 | ★ $386.38 |
| AVG Volume (30 Days) | ★ 1.4M | 999.3K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | ★ 12.57 | 0.47 |
| EPS | 3.76 | ★ 10.76 |
| Revenue | ★ $5,503,000,000.00 | $3,165,286,000.00 |
| Revenue This Year | $8.41 | $104.66 |
| Revenue Next Year | $5.28 | $10.53 |
| P/E Ratio | ★ $23.14 | $28.06 |
| Revenue Growth | 5.97 | ★ 6.99 |
| 52 Week Low | $83.87 | $275.05 |
| 52 Week High | $110.11 | $414.15 |
| Indicator | VLTO | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 29.30 | 41.83 |
| Support Level | N/A | $281.62 |
| Resistance Level | $103.43 | $308.14 |
| Average True Range (ATR) | 1.77 | 8.63 |
| MACD | -0.41 | 2.99 |
| Stochastic Oscillator | 12.88 | 63.96 |
Veralto is a diversified industrial firm organized into two segments: water quality, product quality, and innovation. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.5 billion in revenue in 2025.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.